Oct 23, 2026
San Diego, California Oct 22, 2026 (Issuewire.com) - Ting Therapeutics Advances TT004 into Phase Ib Clinical Trial as a Potential Chemoprotective Therapy for Cisplatin-Treated Patients
Ting Therapeutics, Inc., a biotechnology company developing therapies for treatment-related tissue injury, today announced that its lead candidate, TT004, has received IND approval in China and is advancing into Phase Ib clinical development as a potential chemoprotective therapy for patients receiving cisplatin chemotherapy.
Cisplatin is a highly effective cancer treatment, but its toxicities can substantially limit therapy. Approximately 40% of patients discontinue or modify chemotherapy because of treatment-related toxicities. Cisplatin can also cause permanent hearing loss in up to 80% of patients and acute kidney injury in approximately 30% of patients.
TT004 is designed to protect normal tissues from cisplatin toxicity while preserving its anticancer activity. In preclinical studies, TT004 increased survival following cisplatin exposure three-fold and reduced cisplatin-induced hearing loss and kidney injury by approximately 70%, without compromising cisplatin's anticancer effects.
"These findings support our vision of TT004 as a chemoprotective therapy that could improve the tolerability of cisplatin while maintaining its anticancer efficacy," said Jian Zuo, PhD, Co-Founder and CEO of Ting Therapeutics. "Our goal is to reduce the suffering caused by cisplatin treatment-related toxicities, help more patients receive and complete effective chemotherapy, and improve their long-term quality of life."
Ting Therapeutics recently licensed its China rights for TT004 to Rising Dragon, a Chinese biotechnology company, for development in China. The companies jointly developed TT004 as an oral tablet and obtained IND approval from China's Center for Drug Evaluation (CDE) for first-in-human clinical evaluation.
The Phase Ib trial, conducted in collaboration with oncologists and otolaryngologists at Eye and ENT Hospital of Fudan University in Shanghai, will evaluate the safety and tolerability of oral TT004 administered with standard-of-care cisplatin chemotherapy in patients with head and neck cancer. The study has received institutional ethics approval and is preparing to initiate patient recruitment.
TT004's protective effects have been demonstrated only in preclinical models and have not yet been shown in humans. This trial is the first clinical evaluation of TT004 and an important step toward determining whether these effects can be translated to cancer patients.
About Ting Therapeutics
Founded in 2018, Ting Therapeutics, Inc. develops novel and repurposed therapeutics to prevent and treat hearing loss and other treatment-related tissue injuries. The Company's pipeline targets hearing loss associated with chemotherapy, noise exposure, antibiotics, aging, and other causes.
Contact:
Jian Zuo, PhD, Co-Founder & CEO
Ting Therapeutics, Inc.
6868 Nancy Ridge Dr., San Diego, CA 92121
[email protected]
Source :Ting Therapeutics, Inc.
This article was originally published by IssueWire. Read the original article here.
Diplomats from the EU’s 27 member states were pressured this week to lift sanctions on Yusha Group, a Chinese textiles manufacturer accused of selling sensitive European technology to Russian buyers. In exchange, Beijing has pledged that the company will refrain from shipping banned items to Russian military-linked buyers. It will also remove German company Sindlhauser Materials from its own export controls list, according to multiple sources familiar with the affair. The unusual quid pro quo –...
At least 16 people were killed and 32 more injured when a strong 7.0-magnitude earthquake struck China’s western Tibet autonomous region late on Thursday, state news agency Xinhua said, citing local authorities. More than 300 houses collapsed in the earthquake, which struck on Thursday at 10.33pm. Officials were still evaluating the damage, and disaster relief work was ongoing, Xinhua said. The epicentre of the quake was located in a mountainous area about 190km (120 miles) east-northeast of...
Tom Skerritt, the Emmy-winning actor who embodied a solid, wry authority figure, whether as a flight instructor in “Top Gun,” a tough-but-fair sheriff on TV's “Picket Fences” or the doomed captain of “Alien,” has died.
Flight interruptions have gripped the United States as severe weather affects several key airports. Gusty winds in Boston and New York have led to extensive delays, while thunderstorms in Phoenix and downpours in California have caused further operational chaos. Travelers are strongly urged to verify their flight statuses and review cancellation policies with their airlines.
Mohammad Bagher Ghalibaf will attend the two-day BRICS Parliamentary Forum in India starting October 26. His role as a negotiator in conflicts with Israel and the US is significant. Lok Sabha Speaker Om Birla addressed the forum's details in a recent press conference. Also, discussions about possible impeachment of Chief Election Commissioner Gyanesh Kumar were mentioned by Birla.
Mohammad Bagher Ghalibaf will attend the two-day BRICS Parliamentary Forum in India starting October 26. His role as a negotiator in conflicts with Israel and the US is significant. Lok Sabha Speaker Om Birla addressed the forum's details in a recent press conference. Also, discussions about possible impeachment of Chief Election Commissioner Gyanesh Kumar were mentioned by Birla.
India's investment appeal is currently being tested as global capital flows shift towards other regions. While private capital investors see potential, sustaining growth requires policy improvements and stronger emerging industry engagement. India's growth forecast for 2026-27 has been increased, indicating positive long-term expectations. The country must address structural disadvantages to enhance its competitiveness on the global stage.
India's investment appeal is currently being tested as global capital flows shift towards other regions. While private capital investors see potential, sustaining growth requires policy improvements and stronger emerging industry engagement. India's growth forecast for 2026-27 has been increased, indicating positive long-term expectations. The country must address structural disadvantages to enhance its competitiveness on the global stage.
The Cabinet Secretariat reviewed communications from Election Commissioners Sukhbir Singh Sandhu and Vivek Joshi regarding an ECI officer. They indicated that Deputy EC Maneesh Garg acted without proper approval and did not follow protocols. These communications were considered unofficial and not from the commission as a whole. They expressed concern over Garg's actions after receiving repeated instructions against such conduct.
The Cabinet Secretariat reviewed communications from Election Commissioners Sukhbir Singh Sandhu and Vivek Joshi regarding an ECI officer. They indicated that Deputy EC Maneesh Garg acted without proper approval and did not follow protocols. These communications were considered unofficial and not from the commission as a whole. They expressed concern over Garg's actions after receiving repeated instructions against such conduct.
Market participants and economists now expect a 25-bps increase in the December and February reviews. A further 25-bps increase in April isn't ruled out if crude oil prices remain persistently above $100. One basis point is a hundredth of a percentage point. "After the minutes were released, we think the probability of a consecutive hike in December has increased. Our terminal rate forecast is now at 6% for this hiking cycle and we expect the cycle to be rather shallow," Barclays said in a note.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.